Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.

Drug costs_1B_546120055_1200.jpg

Amgen Inc. has found a way to help US patients with high-risk cardiovascular disease who are covered by Medicare Part D plans spend the same amount of money out of their own pockets for Repatha (evolocumab) as patients covered by commercial plans.

Because Medicare Part D co-payments are based on Repatha's current list price of $14,523, those individuals may pay as much...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access